Zealand Pharma A/S
OTC:ZLDPF

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
OTC:ZLDPF
Watchlist
Price: 63.42 USD
Market Cap: 4.5B USD
Have any thoughts about
Zealand Pharma A/S?
Write Note

Relative Value

The Relative Value of one ZLDPF stock under the Base Case scenario is 16.51 USD. Compared to the current market price of 63.42 USD, Zealand Pharma A/S is Overvalued by 74%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZLDPF Relative Value
Base Case
16.51 USD
Overvaluation 74%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
5
Median 3Y
114
Median 5Y
74.1
Industry
6.8
Forward
7.5
vs History
vs Industry
Median 3Y
-22.8
Median 5Y
-12.9
Industry
21.9
Forward
60.2
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-14.2
Industry
19.5
vs History
vs Industry
Median 3Y
-13.1
Median 5Y
-11.4
Industry
23.4
vs History
98
vs Industry
20
Median 3Y
9.6
Median 5Y
6.8
Industry
2.4
vs History
12
vs Industry
5
Median 3Y
105.7
Median 5Y
73.2
Industry
7.2
Forward
5.3
vs History
12
vs Industry
3
Median 3Y
88.5
Median 5Y
58.8
Industry
9.1
vs History
vs Industry
Median 3Y
-18
Median 5Y
-13.6
Industry
3.9
Forward
278
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-12.7
Industry
3.8
Forward
11.3
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-12.2
Industry
4.4
vs History
vs Industry
Median 3Y
-20.2
Median 5Y
-11.4
Industry
3.5
vs History
17
vs Industry
8
Median 3Y
54.5
Median 5Y
31.6
Industry
4.4

Multiples Across Competitors

ZLDPF Competitors Multiples
Zealand Pharma A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
OTC:ZLDPF
28.7B USD 515.8 -24.2 -14.9 -14.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 976 450.8 -166 237.9 -201 865.8 -199 562.3
US
Abbvie Inc
NYSE:ABBV
322.5B USD 5.6 77.8 14.9 22
US
Amgen Inc
NASDAQ:AMGN
145.9B USD 4.3 24.6 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
132.7B USD 4.6 22.3 9.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.1B USD 10 -112.4 23.8 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 014.2 -514 -559.7 -544.7
AU
CSL Ltd
ASX:CSL
119.4B AUD 5 27.9 17.2 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.7B USD 4.6 14.4 13 14.5
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.5 -64.1 -57.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.7B USD 16.1 -140.4 -625 -313.2
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average P/S: 3 179 913.7
515.8
205%
2.5
FR
Pharnext SCA
OTC:PNEXF
34 976 450.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 014.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
5%
0.9
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
29%
0.6
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
OTC:ZLDPF
Average P/E: 33.4
Negative Multiple: -24.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 237.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -112.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
7%
2.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -140.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBITDA: 15.3
Negative Multiple: -14.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 865.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -625 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBIT: 19.8
Negative Multiple: -14.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 562.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -544.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.2 N/A N/A